$72.45
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. The company is headquartered in Minneapolis, Minnesota and currently employs 3,100 full-time employees. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers. This segment also manufactures and sells fully automated multiomic spatial biology instrumentation and advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use.
Country

US

CEO

Mr. Kim Kelderman

IPO date

1989

Employees

3,100

ISIN

US09073M1045

Key stats

Open

$72.50

Volume

5.47M

Market cap

$11.36B

Prev. close

$72.45

Impl / hst vl

-

Open interest

$0.00

$72.44

Day’s Range

$72.52

$43.20

52W Range

$72.69

Valuation

44
Valuation score
Fairly Valued
P/E
62.54
P/S
9.36
P/B
5.40
Current ratio
4.55
Debt / Equity
-
ROE
8.90%
Gross margin
66.02%
Income growth
7.06%
FCF growth
12.07

Sep

4

Dividends

The last payment date was Sep 4, 2026

Div. per Share

$0.08

Div. Yield

0.11%

Payout Ratio

-

Div. Growth YoY

0.00%

Analysts estimates

Consensus rating
Hold

The average rating from top 15 analysts indicates that stock may significantly underperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$71.42
The top 14 analysts forecasts that 12-month price may decrease by 1.42%, with a low of $50.50 and a high of $78.75
$50.50
Low
$71.42
Avg
$78.75
High
Current price

Earnings

Q2 ‘26 revenue
$321.19M
Q2 ‘26 net income
$54.64M
Revenue
Net income
Previous EPS
$0.53
Estimate EPS
$0.53
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply